中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 5
May  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(5): 1189-1192

Research advances in anti-hepatitis B virus therapy targeting covalently closed circular DNA

DOI: 10.3969/j.issn.1001-5256.2021.05.044

  • Department of Hepatology, The First Hospital of Jilin University, Changchun 130000, China

  • Received Date: 2020-10-12
  • Accepted Date: 2020-11-23
  • Published Date: 2021-05-20
    Abstract
  • The incurable chronic infection caused by hepatitis B virus (HBV) is the major health burden worldwide. Covalently closed circular DNA (cccDNA) exists in the nucleus of infected cells as a stable minichromosome, and when a new therapy realizes inactivation or eliminates persistent cccDNA in infected hepatocytes, the natural process of chronic infection and long-term antiviral therapy will no longer exist. This article introduces the methods targeting cccDNA, such as gene editing and epigenetic modification, so as to achieve the complete cure of HBV infection.

     

    • FullText(HTML)
  • loading
    • References(39)
  • [1]
    World Health Organization. Global hepatitis report[R]. Geneva: WHO, 2017: 1-83.
    [2]
    BLUMBERG BS, ALTER HJ, VISNICH S. A "NEW" antigen in leukemia sera[J]. JAMA, 1965, 191: 541-546. DOI: 10.1001/jama.1965.03080070025007.
    [3]
    SUMMERS J, MASON WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate[J]. Cell, 1982, 29(2): 403-415. DOI: 10.1016/0092-8674(82)90157-x.
    [4]
    HU J, PROTZER U, SIDDIQUI A. Revisiting hepatitis B virus: Challenges of curative therapies[J]. J Virol, 2019, 93(20): e01032-19. DOI: 10.1128/JVI.01032-19.
    [5]
    GUO JT, GUO H. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics[J]. Antiviral Res, 2015, 122: 91-100. DOI: 10.1016/j.antiviral.2015.08.005.
    [6]
    ZHU A, LIAO X, LI S, et al. HBV cccDNA and its potential as a therapeutic target[J]. J Clin Transl Hepatol, 2019, 7(3): 258-262. DOI: 10.14218/JCTH.2018.00054.
    [7]
    LIN CL, KAO JH. Review article: Novel therapies for hepatitis B virus cure - advances and perspectives[J]. Aliment Pharmacol Ther, 2016, 44(3): 213-222. DOI: 10.1111/apt.13694.
    [8]
    LIU S, XIN Y. HBV cccDNA: The stumbling block for treatment of HBV infection[J]. J Clin Transl Hepatol, 2019, 7(3): 195-196. DOI: 10.14218/JCTH.2019.00047.
    [9]
    TANG L, COVERT E, WILSON E, et al. Chronic hepatitis B infection: A review[J]. JAMA, 2018, 319(17): 1802-1813. DOI: 10.1001/jama.2018.3795.
    [10]
    BARTENSCHLAGER R, URBAN S, PROTZER U. Towards curative therapy of chronic viral hepatitis[J]. Z Gastroenterol, 2019, 57(1): 61-73. DOI: 10.1055/a-0824-1576.
    [11]
    BLOCK TM, GUO H, GUO JT. Molecular virology of hepatitis B virus for clinicians[J]. Clin Liver Dis, 2007, 11(4): 685-706, vii. DOI: 10.1016/j.cld.2007.08.002.
    [12]
    DONG J, YING J, QIU X, et al. Advanced strategies for eliminating the cccDNA of HBV[J]. Dig Dis Sci, 2018, 63(1): 7-15. DOI: 10.1007/s10620-017-4842-1.
    [13]
    SETO WK, LO YR, PAWLOTSKY JM, et al. Chronic hepatitis B virus infection[J]. Lancet, 2018, 392(10161): 2313-2324. DOI: 10.1016/S0140-6736(18)31865-8.
    [14]
    TU T, BUDZINSKA MA, VONDRAN F, et al. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles[J]. J Virol, 2018, 92(11): e02007-e02017. DOI: 10.1128/JVI.02007-17.
    [15]
    HU J, SEEGER C. Hepadnavirus genome replication and persistence[J]. Cold Spring Harb Perspect Med, 2015, 5(7): a021386. DOI: 10.1101/cshperspect.a021386.
    [16]
    SEEGER C, MASON WS. Molecular biology of hepatitis B virus infection[J]. Virology, 2015, 479-480: 672-686. DOI: 10.1016/j.virol.2015.02.031.
    [17]
    NASSAL M. HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J]. Gut, 2015, 64(12): 1972-1984. DOI: 10.1136/gutjnl-2015-309809.
    [18]
    GAO W, HU J. Formation of hepatitis B virus covalently closed circular DNA: Removal of genome-linked protein[J]. J Virol, 2007, 81(12): 6164-6174. DOI: 10.1128/JVI.02721-06.
    [19]
    WU M, LI J, YUE L, et al. Establishment of Cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays[J]. Antiviral Res, 2018, 152: 45-52. DOI: 10.1016/j.antiviral.2018.02.007.
    [20]
    BLOOM K, MAEPA MB, ELY A, et al. Gene therapy for chronic HBV-can we eliminate cccDNA?[J]. Genes (Basel), 2018, 9(4). DOI: 10.3390/genes9040207.
    [21]
    KITAMURA K, QUE L, SHIMADU M, et al. Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus[J]. PLoS Pathog, 2018, 14(6): e1007124. DOI: 10.1371/journal.ppat.1007124.
    [22]
    SLAGLE BL, BOUCHARD MJ. Role of HBx in hepatitis B virus persistence and its therapeutic implications[J]. Curr Opin Virol, 2018, 30: 32-38. DOI: 10.1016/j.coviro.2018.01.007.
    [23]
    SEKIBA K, OTSUKA M, OHNO M, et al. Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 interaction[J]. Cell Mol Gastroenterol Hepatol, 2019, 7(2): 297-312. DOI: 10.1016/j.jcmgh.2018.10.010.
    [24]
    LEWANDOWSKA M, PIEKARSKA A. New directions in hepatitis B therapy research[J]. Clin Exp Hepatol, 2017, 3(3): 119-126. DOI: 10.5114/ceh.2017.68831.
    [25]
    KENNEDY EM, KORNEPATI AV, CULLEN BR. Targeting hepatitis B virus cccDNA using CRISPR/Cas9[J]. Antiviral Res, 2015, 123: 188-192. DOI: 10.1016/j.antiviral.2015.10.004.
    [26]
    SEEGER C, SOHN JA. Complete spectrum of CRISPR/Cas9-induced mutations on HBV cccDNA[J]. Mol Ther, 2016, 24(7): 1258-1266. DOI: 10.1038/mt.2016.94.
    [27]
    YANG HC, CHEN PJ. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA[J]. Virus Res, 2018, 244: 304-310. DOI: 10.1016/j.virusres.2017.06.010.
    [28]
    KOSTYUSHEV D, BREZGIN S, KOSTYUSHEVA A, et al. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus[J]. Cell Mol Life Sci, 2019, 76(9): 1779-1794. DOI: 10.1007/s00018-019-03021-8.
    [29]
    WEBER ND, STONE D, SEDLAK RH, et al. AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication[J]. PLoS One, 2014, 9(5): e97579. DOI: 10.1371/journal.pone.0097579.
    [30]
    BLOOM K, ELY A, MUSSOLINO C, et al. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases[J]. Mol Ther, 2013, 21(10): 1889-1897. DOI: 10.1038/mt.2013.170.
    [31]
    DREYER T, NICHOLSON S, ELY A, et al. Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus[J]. Biochem Biophys Res Commun, 2016, 478(4): 1563-1568. DOI: 10.1016/j.bbrc.2016.08.152.
    [32]
    BELLONI L, ALLWEISS L, GUERRIERI F, et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome[J]. J Clin Invest, 2012, 122(2): 529-537. DOI: 10.1172/JCI58847.
    [33]
    PARK HK, MIN BY, KIM NY, et al. Short hairpin RNA induces methylation of hepatitis B virus covalently closed circular DNA in human hepatoma cells[J]. Biochem Biophys Res Commun, 2013, 436(2): 152-155. DOI: 10.1016/j.bbrc.2013.04.108.
    [34]
    QIAN G, HU B, ZHOU D, et al. NIRF, a novel ubiquitin ligase, inhibits hepatitis B virus replication through effect on HBV core protein and H3 histones[J]. DNA Cell Biol, 2015, 34(5): 327-332. DOI: 10.1089/dna.2014.2714.
    [35]
    WEI ZQ, ZHANG YH, KE CZ, et al. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation[J]. World J Gastroenterol, 2017, 23(34): 6252-6260. DOI: 10.3748/wjg.v23.i34.6252.
    [36]
    SONG M, SUN Y, TIAN J, et al. Silencing retinoid X receptor alpha expression enhances early-stage hepatitis B virus infection in cell cultures[J]. J Virol, 2018, 92(8). DOI: 10.1128/JVI.01771-17.
    [37]
    YUAN Y, ZHAO K, YAO Y, et al. HDAC11 restricts HBV replication through epigenetic repression of cccDNA transcription[J]. Antiviral Res, 2019, 172: 104619. DOI: 10.1016/j.antiviral.2019.104619.
    [38]
    FANNING GC, ZOULIM F, HOU J, et al. Therapeutic strategies for hepatitis B virus infection: Towards a cure[J]. Nat Rev Drug Discov, 2019, 18(11): 827-844. DOI: 10.1038/s41573-019-0037-0.
    [39]
    ZAI WJ, CHEN JL, YUAN ZH. Regulatory mechanisms of the transcription and metabolism of hepatitis B virus covalently closed circular DNA and strategies for silencing and elimination[J]. J Clin Hepatol, 2020, 36(5): 983-988. DOI: 10.3969/j.issn.1001-5256.2020.05.006.

    宰文静, 陈捷亮, 袁正宏. HBV cccDNA转录代谢调控机制及沉默清除策略[J]. 临床肝胆病杂志, 2020, 36(5): 983-988. DOI: 10.3969/j.issn.1001-5256.2020.05.006.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (547) PDF downloads(69) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return